Cannabis M&A Heats Up: 3 Takeover Targets Wall Street Is Watching
By Sheeba M. | April 18, 2026 Cannabis M&A Heats Up: 3 Takeover Targets Wall Street Is Watching TL;DR: With MSO balance sheets stabilizing and institutional capital returning, a new wave of cannabis M&A is inevitable. These three mid-tier operators look like prime acquisition candidates. The cannabis sector is quietly positioning itself for its next […]
Curaleaf’s International Push: Can a US-Centric MSO Win in European Cannabis Markets?
By Sheeba M. | April 18, 2026 Curaleaf’s International Push: Can a US-Centric MSO Win in European Cannabis Markets? TL;DR: Curaleaf has been aggressively acquiring European cannabis assets — but EU cannabis markets operate under entirely different regulatory rules than US state markets. The opportunity is massive; so is the execution risk. Curaleaf Holdings (CSE: […]
Cresco Labs Expansion Strategy: Why the Vertical Integration Play Could Pay Off in 2026
By Sheeba M. | April 18, 2026 Cresco Labs Expansion Strategy: Why the Vertical Integration Play Could Pay Off in 2026 TL;DR: Cresco Labs is doubling down on full vertical integration across its retail and wholesale arms — a strategy that’s compressing margins today but sets up a powerful cost advantage as cannabis markets mature […]
The Cannabis M&A Wave Is Building Again — and This Time the Targets Look Different
By Sheeba M. | April 18, 2026 The Cannabis M&A Wave Is Building Again — and This Time the Targets Look Different TL;DR: After a two-year deal-making drought, cannabis M&A is perking up — but the strategic logic has changed. Buyers want profitable assets, not just revenue scale. That’s great news for holders of well-run […]
Small-Cap Cannabis Operators Are Quietly Outperforming the Big MSOs — Here’s Why
By Sheeba M. | April 18, 2026 Small-Cap Cannabis Operators Are Quietly Outperforming the Big MSOs — Here’s Why TL;DR: While Curaleaf and Trulieve fight margin compression, a cohort of sub-$500M cannabis operators are posting 30%+ revenue growth with leaner cost structures. The market is starting to notice. The cannabis industry’s center of gravity may […]
FDA just fast-tracked a cannabis-derived sleep drug — here’s the investment angle
By Sheeba M. | April 17, 2026 FDA just fast-tracked a cannabis-derived sleep drug — here’s the investment angle TL;DR: A new FDA Breakthrough Therapy designation for a cannabis-derived insomnia treatment could unlock a $4B market — and the licensing partners, not the originator, may offer the better risk-reward. The FDA’s accelerated approval pathway has […]
Cannabis REITs Are quietly yielding 9% while MSO stocks recover
By Sheeba M. | April 17, 2026 Cannabis REITs Are quietly yielding 9% while MSO stocks recover TL;DR: While investors chase MSO equity, cannabis real estate investment trusts are quietly delivering 7-10% dividend yields with far less volatility — a hidden gem in the sector. The cannabis industry’s recovery is producing an unlikely winner: real […]
Trulieve’s Florida Dominance Faces Test as Adult-Use Rollout Accelerates
By Sheeba M. | April 17, 2026 Trulieve’s Florida Dominance Faces Test as Adult-Use Rollout Accelerates TL;DR: Trulieve controls nearly 40% of Florida’s dispensary count, but incoming adult-use competition from MSOs with deep pockets could erode its market share — the stock is cheap enough to bet on, but the margin of safety is thinner […]
Green Thumb Industries Expands Retail Footprint as Michigan Market Matures
By Sheeba M. | April 17, 2026 Green Thumb Industries Expands Retail Footprint as Michigan Market Matures TL;DR: Green Thumb Industries is aggressively opening new dispensaries across Michigan and Ohio — a signal management expects strong Q2 revenue growth as recreational legalization spreads in the Midwest. Green Thumb Industries (GTBIF) is doubling down on retail […]
Canadian LPs Pivot to U.S. Hemp Markets as Domestic Sales Stall
By Sheeba M. | April 17, 2026 Canadian LPs Pivot to U.S. Hemp Markets as Domestic Sales Stall TL;DR: Canadian licensed producers like Canopy Growth are aggressively acquiring U.S. hemp-derived CBD and wellness assets to compensate for flatlined Canadian recreational sales. The strategy carries regulatory risk but addresses a $20B+ addressable market. Canada’s legal cannabis […]